from 2 phase 3 monotherapy randomized, double- blind ... goldblum.pdf · prespecified mh...

1
KEY RESULTS Proportion of Patients Achieving EASI50 Response at Week 16 Efficacy of Baricitinib in Patients With Atopic Dermatitis and Atopic Comorbidities: Results of Pooled Data From 2 Phase 3 Monotherapy Randomized, Double-blind, Placebo-Controlled 16-Week Trials (BREEZE-AD1 and BREEZE-AD2) Andreas Wollenberg, 1 Mark Boguniewicz, 2 Jeffrey B. Travers, 3 Jacob P. Thyssen, 4 Orin Goldblum, 5 Susan G. Ball, 5 Luna Sun, 5 Sherry Chen, 6 Jonathan I. Silverberg 7 1 Ludwig Maximillian University, Munich, Germany; 2 National Jewish Health, Denver, USA; 3 Wright State University, Dayton, USA; 4 University of Copenhagen, Herlev and Gentofte Hospital Department of Dermatology and Allergy, Hellerup, Denmark; 5 Eli Lilly and Company, Indianapolis, USA; 6 Syneos Health, Morrisville, USA; 7 Northwestern University, School of Medicine, Evanston, USA American Academy of Allergy Asthma & Immunology 2020 (AAAAI); Philadelphia, USA; 13-16 March 2020 Study was sponsored by Eli Lilly and Company and Incyte Corporation BACKGROUND Asthma and allergic rhinitis are frequent atopic comorbidities in atopic dermatitis (AD) and may influence the management of patients with AD 1 Baricitinib is an oral selective and reversible inhibitor of Janus kinase (JAK)1 and JAK2 The efficacy and safety of baricitinib were evaluated in adult patients with moderate- to-severe AD and a history of inadequate response or intolerance to existing topical therapies in 2 Phase 3 studies, BREEZE-AD1 (NCT03334396) and BREEZE-AD2 (NCT03334422) 2 BREEZE-AD1 and BREEZE-AD2 were conducted in multiple countries, excluding North America OBJECTIVE To assess the efficacy and safety of baricitinib at Week 16 in patients with ≥1 atopic comorbidity at baseline in BREEZE-AD1 and BREEZE-AD2 CONCLUSIONS In adult patients with moderate-to-severe AD with comorbid atopic conditions, baricitinib treatment resulted in clinically meaningful improvements in skin symptoms, itch, and sleep disturbance In general, there were no treatment-effect differences between groups of patients with or without comorbidity The only significant treatment-effect differences between patients with or without comorbidity were observed for ADSS Item 2, and the difference was based on magnitude, not on direction Overall safety outcomes for patients with atopic comorbidities were similar to outcomes in the overall trial population 2 Scan for full poster and/or slideset. 610 REFERENCES 1. Silverberg JI. Clin Dermatol. 2017;35:360-366. 2. Simpson EL, et al. Br J Dermatol. 2020 Jan 29 [online ahead of print]. DOI: 10.1111/bjd.18898. ABBREVIATIONS AD=atopic dermatitis; ADSS=Atopic Dermatitis Sleep Scale; AE=adverse event; BARI=baricitinib; EASI=Eczema Area and Severity Index; EASI50=Eczema Area and Severity Index 50% improvement; IGA=Investigator Global Assessment; LS=least squares; MH=medical history; NRS=Numeric Rating Scale; PBO=placebo; QD=once daily; TEAE=treatment-emergent adverse event; TCS=topical corticosteroid; W=with; W/O=without DISCLOSURES A. Wollenberg has received grants as an investigator and/or honoraria and/or consulting fees from: Almirall, Anacor Pharmaceuticals, Beiersdorf, Eli Lilly and Company, Galderma, LEO Pharma, MedImmune, Novartis, Pfizer, Pierre Fabre, Regeneron, and Sanofi Genzyme; M. Boguniewicz has been an advisory board member for: Eli Lilly and Company; J. B. Travers has received consulting fees from: Eli Lilly and Company; J. P. Thyssen has been an advisory board member, received speaker honoraria, and/or has participated in clinical studies for: AbbVie, Eli Lilly and Company, LEO Pharma, Pfizer, Regeneron, and Sanofi Genzyme; O. Goldblum, S. G. Ball, and L. Sun are current employees and shareholders of Eli Lilly and Company; S. Chen is a current employee of Syneos Health; J. I. Silverberg has received grants as an investigator, honoraria, and/ or consulting fees from: AbbVie, AnaptysBio, Arena Pharmaceuticals, Asana BioSciences, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Glenmark Pharmaceuticals, Kiniksa Pharmaceuticals, LEO Pharma, Luna Pharma, MedImmune, Menlo Therapeutics, Novartis, Pfizer, Regeneron, and Sanofi This study was sponsored by Eli Lilly and Company and Incyte Corporation. Medical writing assistance was provided by Ella Lineham, PhD, of ProScribe Envision Pharma Group, and was funded by Eli Lilly and Company METHODS Study Design, BREEZE-AD1 and BREEZE-AD2 W16 c W -5 16 b 0 -5 1 2 4 8 12 Primary endpoint IGA™ of 0 or 1 c Randomization 2:1:1:1 PBO:1-mg:2-mg:4-mg AD1 N=624 AD2 N=615 Screening and washout a BARI 4-mg QD PBO QD BARI 1-mg QD BARI 2-mg QD a All patients washed out of AD treatments (2-week washout for TCS and 4-week washout for systemic therapies) b Patients who did not enroll into BREEZE-AD3 completed a post-treatment follow-up period (28 days) c Proportion of participants achieving IGA of 0 or 1 with a ≥2-point improvement Patients experiencing unacceptable worsening of AD symptoms could receive rescue therapy at any time. Rescue therapy comprised triamcinolone 0.1% cream and/or hydrocortisone 2.5% ointment (or an equivalent TCS cream/ointment if these formulations were not available). TCS use was not allowed during the treatment period except as rescue Key Eligibility Criteria ≥18 years old, and diagnosis of AD for ≥12 months Moderate-to-severe AD at Screening and Randomization, defined as: Validated Investigator Global Assessment (IGA) of AD score of 3 or 4 (severe) Eczema Area and Severity Index (EASI) ≥16 Body surface area involvement ≥10% Inadequate response or intolerance to ≥1 topical medication <6 months prior to Screening Patients who failed systemic therapies and intended to treat AD within 6 months preceding Screening were also considered as surrogates for having inadequate response to topical medication No topical corticosteroid (TCS) use allowed during treatment period, except as rescue Assessments Efficacy Assessments (at Week 16) Proportion of patients achieving ≥50% improvement in EASI (EASI50) Proportion of patients achieving IGA of 0, 1, or 2 Proportion of patients achieving a 4-point improvement in itch Numeric Rating Scale (NRS) EASI percentage change from baseline through Week 16 Itch NRS percentage change from baseline through Week 16 Atopic Dermatitis Sleep Scale (ADSS) Item 2 percentage change from baseline at Week 16 ADSS Item 2 = How many times did your itch cause you to wake up last night? Safety Assessments Frequency of adverse events and overview of infection in patients with and without atopic comorbidities a RESULTS Baseline Characteristics and Disease Activity a Prespecified medical history comorbidity (with) includes: adverse drug reaction, allergy to arthropod sting, allergy to chemicals, anaphylactic reaction, asthma, conjunctivitis allergic, dermatitis contact, food allergy, rhinitis allergic, seasonal allergy, and urticaria a Terms in logistic regression: treatment, MH comorbidity, baseline disease severity (IGA), and treatment-by-MH-comorbidity and baseline b Terms in MMRM: treatment, region, baseline disease severity (IGA), visit, MH comorbidity, treatment-by-visit-interaction, treatment-by-MH comorbidity-interaction, visit-by-MH comorbidity-interaction, and treatment-by-visit-by-MH-comorbidity-interaction, baseline, baseline-by-visit-interaction, and baseline-by-MH comorbidity c Terms in ANCOVA: treatment, baseline value, region, baseline disease severity (IGA), MH comorbidity, and treatment-by- MH-comorbidity-interaction d Prespecified MH comorbidity includes: adverse drug reaction, allergy to arthropod sting, allergy to chemicals, anaphylactic reaction, asthma, conjunctivitis allergic, dermatitis contact, food allergy, rhinitis allergic, seasonal allergy, and urticaria Statistical Analysis Population: Pooled data from BREEZE-AD1 and BREEZE-AD2 clinical trials For discrete efficacy outcomes: Data were analyzed using logistic regression a Observations after TCS rescue were excluded and imputed in monotherapy analyses; observations after TCS rescue were included in TCS analyses Non-responder imputation was used for missing data For continuous efficacy outcomes: A mixed-model repeated measures (MMRM) analysis was used for EASI percentage change from baseline and Itch NRS percentage change from baseline as those assessments had multiple visits b Analysis of covariance (ANCOVA) model was used for ADSS Item 2 c Treatment-by-medical-history-comorbidity d -interaction was included in all models to test if treatment effects differ for patients with and without comorbidity There was no adjustment in p-values for multiplicity BREEZE-AD1/AD2 PBO (N=493) BARI 1-mg (N=252) BARI 2-mg (N=246) BARI 4-mg (N=248) Atopic comorbidity W (N=357) W/O (N=136) W (N=177) W/O (N=75) W (N=176) W/O (N=70) W (N=168) W/O (N=80) Age, years 34.9 (12.4) 36.7 (13.8) 34.6 (11.3) 33.8 (11.7) 34.0 (12.2) 38.3 (15.8) 35.2 (13.5) 36.0 (13.8) Male, n (%) 226 (63.3) 76 (55.9) 108 (61.0) 50 (66.7) 107 (60.8) 40 (57.1) 114 (67.9) 51 (63.8) Weight, kg 72.5 (15.1) 72.8 (16.8) 73.9 (17.2) 75.8 (16.0) 74.3 (16.7) 70.8 (14.9) 73.6 (17.3) 73.3 (13.3) Duration since AD diagnosis, years 26.9 (14.1) 22.4 (16.0) 27.0 (13.5) 21.0 (14.1) 25.4 (13.1) 22.5 (16.5) 26.1 (14.4) 18.7 (14.6) IGA, n (%) 3 4 189 (52.9) 168 (47.1) 78 (57.4) 58 (42.6) 96 (54.2) 81 (45.8) 39 (52.0) 35 (46.7) 98 (55.7) 78 (44.3) 34 (48.6) 36 (51.4) 90 (53.6) 78 (46.4) 44 (55.0) 36 (45.0) EASI 32.5 (12.8) 31.7 (13.2) 31.2 (12.3) 30.7 (12.6) 32.0 (13.3) 34.6 (16.0) 32.7 (12.5) 31.9 (13.1) Itch NRS ≥4, n (%) 320 (89.6) 115 (84.6) 149 (84.2) 56 (74.7) 145 (82.4) 61 (87.1) 148 (88.1) 66 (82.5) Baseline demographics and disease activity were similar in patients with or without comorbidity Data are mean (standard deviation) unless stated otherwise Frequency of Medical History Comorbidity n (%) PBO (N=493) BARI 1-mg (N=252) BARI 2-mg (N=246) BARI 4-mg (N=248) Prespecified medical history of comorbidity 357 (72.4) 177 (70.2) 176 (71.5) 168 (67.7) Comorbidity a Asthma 137 (38.4) 67 (37.9) 84 (47.7) 74 (44.0) Allergic conjunctivitis 103 (28.9) 53 (29.9) 49 (27.8) 40 (23.8) Allergic rhinitis 207 (58.0) 111 (62.7) 103 (58.5) 86 (51.2) Contact dermatitis 37 (10.4) 27 (15.3) 22 (12.5) 17 (10.1) Food allergy 149 (41.7) 72 (40.7) 73 (41.5) 63 (37.5) Seasonal allergy 164 (45.9) 78 (44.1) 80 (45.5) 81 (48.2) Urticaria 22 (6.2) 10 (5.6) 14 (8.0) 10 (6.0) The most common comorbidities were asthma, food allergy, allergic rhinitis, and seasonal allergy a ≥5% occurrence, patients with multiple occurrences of the same event are counted under the highest severity The magnitude of response with baricitinib was consistently greater than with placebo There were no significant treatment-effect differences between patients with or without comorbidity ** p≤0.01, *** p≤0.001 vs. PBO Proportion of Patients Achieving Itch NRS ≥4-Point Improvement Response at Week 16 a,b The magnitude of response with baricitinib was consistently greater than with placebo There were no significant treatment-effect differences between patients with or without comorbidity * p≤0.05, ** p≤0.01, *** p≤0.001 vs. PBO a Analysis based on patients with Itch NRS ≥4 at baseline b 0=no itch, 10=worst itch imaginable Proportion of Patients Achieving IGA (0, 1, 2) Response at Week 16 a The magnitude of response with baricitinib was consistently greater than with placebo There were no significant treatment-effect differences between patients with or without comorbidity * p≤0.05, ** p≤0.01, *** p≤0.001 vs. PBO a 0=clear, 4=severe EASI Improvement at Week 16 The change from baseline with baricitinib was consistently greater than with placebo There were no significant treatment-effect differences between patients with or without comorbidity * p≤0.05, ** p≤0.01, *** p≤0.01 vs. PBO a LS mean percentage change from baseline = (LS mean change from baseline / overall total mean at baseline) × 100 Itch Improvement at Week 16 The change from baseline with baricitinib was consistently greater than with placebo There were no significant treatment-effect differences between patients with or without comorbidity * p≤0.05, ** p≤0.01, *** p≤0.01 vs. PBO a ADSS Item 2 = How many times did your itch cause you to wake up last night? b In patients with ADSS Item 2 score >1 at baseline c LS mean percentage change from baseline = (LS mean change from baseline / overall total mean at baseline) × 100 Improvement in Sleep Disturbance Due to Itch at Week 16 a ** p≤0.01, *** p≤0.001 vs. PBO a LS mean percentage change from baseline = (LS mean change from baseline / overall total mean at baseline) × 100 The change from baseline with baricitinib was consistently greater than with placebo There was a significant difference in treatment effect between patients with or without comorbidity (p=0.0143) The difference was based on the magnitude of the difference between baricitinib treatment and placebo; the direction of that difference was the same With Without 0 20 40 60 80 100 Atopic Comorbidity Response (%) ** 11.5 19.9 20.3 26.7 29.0 28.6 32.7 41.3 *** *** *** Monotherapy BARI 1-mg (N=252) BARI 2-mg (N=246) BARI 4-mg (N=248) PBO (N=493) N=357 N=177 N=176 N=168 N=136 N=75 N=70 N=80 With Without 0 20 40 60 80 100 Atopic Comorbidity Response (%) 38.1 51.5 45.8 64.0 61.9 61.4 55.4 63.8 *** *** With TCS Rescue PBO (N=493) BARI 1-mg (N=252) BARI 2-mg (N=246) BARI 4-mg (N=248) N=357 N=177 N=176 N=168 N=136 N=75 N=70 N=80 With Without 0 20 40 60 80 100 Atopic Comorbidity Response (%) * 4.4 2.6 10.1 12.5 16.6 6.6 21.6 21.2 *** *** * *** Monotherapy N=320 N=148 N=145 N=148 N=114 N=56 N=61 N=66 With Without 0 20 40 60 80 100 Atopic Comorbidity Response (%) 15.9 12.3 17.6 19.7 20.7 19.6 28.4 30.3 ** ** With TCS Rescue N=320 N=148 N=145 N=148 N=114 N=56 N=61 N=66 With Without 0 20 40 60 80 100 Atopic Comorbidity Response (%) ** 9.8 17.6 18.6 21.3 25.0 20.0 29.8 32.5 *** ** * Monotherapy PBO (N=493) BARI 1-mg (N=252) BARI 2-mg (N=246) BARI 4-mg (N=248) N=357 N=177 N=176 N=168 N=136 N=75 N=70 N=80 With Without 0 20 40 60 80 100 Atopic Comorbidity Response (%) 31.7 44.1 36.2 46.7 48.9 52.9 50.6 45.0 *** *** With TCS Rescue PBO (N=493) BARI 1-mg (N=252) BARI 2-mg (N=246) BARI 4-mg (N=248) N=357 N=177 N=176 N=168 N=136 N=75 N=70 N=80 n (%) BREEZE-AD1/AD2 PBO (N=493) BARI 1-mg (N=251) BARI 2-mg (N=246) BARI 4-mg (N=248) Atopic comorbidity W (N=357) W/O (N=136) W (N=177) W/O (N=74) W (N=176) W/O (N=70) W (N=168) W/O (N=80) Any TEAE Mild Moderate Severe 213 (59.7) 123 (34.5) 76 (21.3) 14 (3.9) 59 (43.4) 35 (25.7) 22 (16.2) 2 (1.5) 107 (60.5) 53 (29.9) 45 (25.4) 9 (5.1) 28 (37.8) 20 (27.0) 6 (8.1) 2 (2.7) 107 (60.8) 63 (35.8) 38 (21.6) 6 (3.4) 35 (50.0) 25 (35.7) 8 (11.4) 2 (2.9) 107 (63.7) 70 (41.7) 32 (19.0) 5 (3.0) 32 (40.0) 22 (27.5) 10 (12.5) 0 Serious AEs 13 (3.6) 2 (1.5) 9 (5.1) 1 (1.4) 2 (1.1) 1 (1.4) 3 (1.8) 0 Death 0 0 0 0 0 0 0 0 AEs leading to study discontinuation 2 (0.6) 0 3 (1.7) 0 3 (1.7) 0 2 (1.2) 0 With Without -80 -60 -40 -20 0 Atopic Comorbidity LS Mean Percentage Change From Baseline a ** -28.5 -49.1 -58.3 -51.3 -63.3 *** *** EASI Percentage Change From Baseline -41.0 -43.3 -51. 3 -55.5 * ** With Without -80 -60 -40 -20 0 Atopic Comorbidity LS Mean Percentage Change From Baseline a *** -15.0 -25.0 -35.3 -34.4 *** Itch NRS Percentage Change From Baseline -23.4 -28.7 -32.8 -39.4 ** Overview of Adverse Events Most treatment-emergent adverse events were mild or moderate Overview of Treatment-Emergent Infections n (%) BREEZE-AD1/AD2 PBO (N=493) BARI 1-mg (N=251) BARI 2-mg (N=246) BARI 4-mg (N=248) Atopic comorbidity W (N=357) W/O (N=136) W (N=177) W/O (N=74) W (N=176) W/O (N=70) W (N=168) W/O (N=80) Patients with ≥1 infection 111 (31.1) 39 (28.7) 64 (36.2) 13 (17.6) 65 (36.9) 19 (27.1) 63 (37.5) 21 (26.3) Opportunistic infection 0 0 0 0 0 0 0 0 Herpes zoster 1 (0.3) 0 0 0 0 2 (2.9) 0 0 Herpes simplex 10 (2.8) 4 (2.9) 11 (6.2) 2 (2.7) 11 (6.3) 0 8 (4.8) 6 (7.5) Tuberculosis 0 0 0 0 0 0 0 0 Patients with ≥1 skin infection requiring antibiotic treatment 23 (6.4) 7 (5.1) 5 (2.8) 2 (2.7) 12 (6.8) 3 (4.3) 8 (4.8) 2 (2.5) Safety outcomes for patients with atopic comorbidities were similar to outcomes in the overall population 2 PBO (N=493) BARI 2-mg (N=246) BARI 1-mg (N=252) BARI 4-mg (N=248) PBO (N=493) BARI 2-mg (N=246) BARI 1-mg (N=252) BARI 4-mg (N=248) Week Week Week Week Week Week Week Week With Without 0 20 40 60 80 100 Atopic Comorbidity LS Mean Percentage Change From Baseline c 8.2 9.1 12.8 28.5 26.7 19.3 26.7 30.2 Change From Baseline in Nights Without Awakenings, b Observed *** *** *** * *** N=223 N=97 N=90 N=95 N=72 N=37 N=44 N=42 PBO (N=295) BARI 2-mg (N=134) BARI 1-mg (N=135) BARI 4-mg (N=138) PBO (N=435) BARI 2-mg (N=206) BARI 1-mg (N=205) BARI 4-mg (N=214) PBO (N=435) BARI 2-mg (N=206) BARI 1-mg (N=205) BARI 4-mg (N=214)

Upload: others

Post on 29-May-2020

7 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: From 2 Phase 3 Monotherapy Randomized, Double- blind ... Goldblum.pdf · Prespecified MH comorbidity includes: adverse drug reaction, allergy to arthropod sting, allergy to chemicals,

KEY RESULTSProportion of Patients Achieving EASI50 Response at Week 16

Efficacy of Baricitinib in Patients With Atopic Dermatitis and Atopic Comorbidities: Results of Pooled DataFrom 2 Phase 3 Monotherapy Randomized, Double-blind, Placebo-Controlled 16-Week Trials (BREEZE-AD1 and BREEZE-AD2)

Andreas Wollenberg,1 Mark Boguniewicz,2 Jeffrey B. Travers,3 Jacob P. Thyssen,4 Orin Goldblum,5 Susan G. Ball,5 Luna Sun,5 Sherry Chen,6 Jonathan I. Silverberg7

1Ludwig Maximillian University, Munich, Germany; 2National Jewish Health, Denver, USA; 3Wright State University, Dayton, USA; 4University of Copenhagen, Herlev and Gentofte Hospital Department of Dermatology and Allergy, Hellerup, Denmark; 5Eli Lilly and Company, Indianapolis, USA; 6Syneos Health, Morrisville, USA; 7Northwestern University, School of Medicine, Evanston, USA

American Academy of Allergy Asthma & Immunology 2020 (AAAAI); Philadelphia, USA; 13-16 March 2020 Study was sponsored by Eli Lilly and Company and Incyte Corporation

BACKGROUND■ Asthma and allergic rhinitis are

frequent atopic comorbidities in atopic dermatitis (AD) and may influence the management of patients with AD1

■ Baricitinib is an oral selective and reversible inhibitor of Janus kinase (JAK)1 and JAK2

■ The efficacy and safety of baricitinib were evaluated in adult patients with moderate-to-severe AD and a history of inadequate response or intolerance to existing topical therapies in 2 Phase 3 studies, BREEZE-AD1 (NCT03334396) and BREEZE-AD2 (NCT03334422)2

– BREEZE-AD1 and BREEZE-AD2 were conducted in multiple countries, excluding North America

OBJECTIVE■ To assess the efficacy and

safety of baricitinib at Week 16 in patients with≥1 atopic comorbidity at baseline in BREEZE-AD1 and BREEZE-AD2

CONCLUSIONS■ In adult patients with

moderate-to-severe AD with comorbid atopic conditions, baricitinib treatment resulted in clinically meaningful improvements in skin symptoms, itch, and sleep disturbance

■ In general, there were no treatment-effect differences between groups of patients with or without comorbidity

– The only significant treatment-effect differences between patients with or without comorbidity were observed for ADSS Item 2, and the difference was based on magnitude, not on direction

■ Overall safety outcomes for patients with atopic comorbidities were similar to outcomes in the overall trial population2

Scan for full posterand/or slideset.

610

REFERENCES1. Silverberg JI. Clin Dermatol. 2017;35:360-366.2. Simpson EL, et al. Br J Dermatol. 2020 Jan 29 [online ahead of print].

DOI: 10.1111/bjd.18898.

ABBREVIATIONSAD=atopic dermatitis; ADSS=Atopic Dermatitis Sleep Scale; AE=adverse event; BARI=baricitinib; EASI=Eczema Area and Severity Index; EASI50=Eczema Area and Severity Index 50% improvement; IGA=Investigator Global Assessment; LS=least squares; MH=medical history; NRS=Numeric Rating Scale; PBO=placebo; QD=once daily; TEAE=treatment-emergent adverse event; TCS=topical corticosteroid; W=with; W/O=without

DISCLOSURES A. Wollenberg has received grants as an investigator and/or

honoraria and/or consulting fees from: Almirall, AnacorPharmaceuticals, Beiersdorf, Eli Lilly and Company, Galderma, LEO Pharma, MedImmune, Novartis, Pfizer, Pierre Fabre, Regeneron, and Sanofi Genzyme; M. Boguniewicz has been an advisory board member for: Eli Lilly and Company; J. B. Travers has received consulting fees from: Eli Lilly and Company; J. P. Thyssen has been an advisory board member, received speaker honoraria, and/or has participated in clinical studies for: AbbVie, Eli Lilly and Company, LEO Pharma, Pfizer, Regeneron, and Sanofi Genzyme; O. Goldblum, S. G. Ball, and L. Sun are current employees and shareholders of Eli Lilly and Company; S. Chen is a current employee of Syneos Health; J. I. Silverberg has received grants as an investigator, honoraria, and/ or consulting fees from: AbbVie, AnaptysBio, Arena Pharmaceuticals, Asana BioSciences, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Glenmark Pharmaceuticals, Kiniksa Pharmaceuticals, LEO Pharma, Luna Pharma, MedImmune, Menlo Therapeutics, Novartis, Pfizer, Regeneron, and Sanofi

This study was sponsored by Eli Lilly and Company and IncyteCorporation. Medical writing assistance was provided by Ella Lineham, PhD, of ProScribe − Envision Pharma Group, and was funded by Eli Lilly and Company

METHODSStudy Design, BREEZE-AD1 and BREEZE-AD2

W16c

W -5 16b0-5 1 2 4 8 12

Primary endpoint

IGA™ of 0 or 1c

Randomization2:1:1:1

PBO:1-mg:2-mg:4-mg

AD1 N=624AD2 N=615Screening

and washouta

BARI 4-mg QD

PBO QD

BARI 1-mg QD

BARI 2-mg QD

a All patients washed out of AD treatments (2-week washout for TCS and 4-week washout for systemic therapies)b Patients who did not enroll into BREEZE-AD3 completed a post-treatment follow-up period (28 days)c Proportion of participants achieving IGA of 0 or 1 with a ≥2-point improvementPatients experiencing unacceptable worsening of AD symptoms could receive rescue therapy at any time. Rescue therapy comprised triamcinolone 0.1% cream and/or hydrocortisone 2.5% ointment (or an equivalent TCS cream/ointment if these formulations were not available). TCS use was not allowed during the treatment period except as rescue

Key Eligibility Criteria■ ≥18 years old, and diagnosis of AD for

≥12 months■ Moderate-to-severe AD at Screening

and Randomization, defined as:– Validated Investigator Global

Assessment (IGA) of AD score of 3 or 4 (severe)

– Eczema Area and Severity Index (EASI) ≥16

– Body surface area involvement ≥10%■ Inadequate response or intolerance to

≥1 topical medication <6 months prior to Screening– Patients who failed systemic therapies

and intended to treat AD within 6 months preceding Screening were also considered as surrogates for having inadequate response to topical medication

■ No topical corticosteroid (TCS) use allowed during treatment period, except as rescue

AssessmentsEfficacy Assessments (at Week 16) ■ Proportion of patients achieving ≥50%

improvement in EASI (EASI50) ■ Proportion of patients achieving IGA of 0, 1, or 2■ Proportion of patients achieving a 4-point

improvement in itch Numeric Rating Scale (NRS)■ EASI percentage change from baseline through

Week 16■ Itch NRS percentage change from baseline

through Week 16■ Atopic Dermatitis Sleep Scale (ADSS) Item 2

percentage change from baseline at Week 16– ADSS Item 2 = How many times did your

itch cause you to wake up last night?Safety Assessments■ Frequency of adverse events and overview of

infection in patients with and without atopic comorbiditiesa

RESULTSBaseline Characteristics and Disease Activity

a Prespecified medical history comorbidity (with) includes: adverse drug reaction, allergy to arthropod sting, allergy to chemicals, anaphylactic reaction, asthma, conjunctivitis allergic, dermatitis contact, food allergy, rhinitis allergic, seasonal allergy, and urticaria

a Terms in logistic regression: treatment, MH comorbidity, baseline disease severity (IGA), and treatment-by-MH-comorbidity and baselineb Terms in MMRM: treatment, region, baseline disease severity (IGA), visit, MH comorbidity, treatment-by-visit-interaction, treatment-by-MH comorbidity-interaction, visit-by-MH comorbidity-interaction, and treatment-by-visit-by-MH-comorbidity-interaction, baseline, baseline-by-visit-interaction, and baseline-by-MH comorbidityc Terms in ANCOVA: treatment, baseline value, region, baseline disease severity (IGA), MH comorbidity, and treatment-by-MH-comorbidity-interactiond Prespecified MH comorbidity includes: adverse drug reaction, allergy to arthropod sting, allergy to chemicals, anaphylactic reaction, asthma, conjunctivitis allergic, dermatitis contact, food allergy, rhinitis allergic, seasonal allergy, and urticaria

Statistical Analysis■ Population: Pooled data from BREEZE-AD1 and BREEZE-AD2 clinical trials■ For discrete efficacy outcomes:

– Data were analyzed using logistic regressiona

– Observations after TCS rescue were excluded and imputed in monotherapy analyses; observations after TCS rescue were included in TCS analyses

– Non-responder imputation was used for missing data■ For continuous efficacy outcomes:

− A mixed-model repeated measures (MMRM) analysis was used for EASI percentage change from baseline and Itch NRS percentage change from baseline as those assessments had multiple visitsb

− Analysis of covariance (ANCOVA) model was used for ADSS Item 2c

■ Treatment-by-medical-history-comorbidityd-interaction was included in all models to test if treatment effects differ for patients with and without comorbidity

■ There was no adjustment in p-values for multiplicity

BREEZE-AD1/AD2

PBO(N=493)

BARI1-mg

(N=252)

BARI2-mg

(N=246)

BARI4-mg

(N=248)

Atopic comorbidityW

(N=357)W/O

(N=136)W

(N=177)W/O

(N=75)W

(N=176)W/O

(N=70)W

(N=168)W/O

(N=80)

Age, years 34.9 (12.4) 36.7 (13.8) 34.6 (11.3) 33.8 (11.7) 34.0 (12.2) 38.3 (15.8) 35.2 (13.5) 36.0 (13.8)

Male, n (%) 226 (63.3) 76 (55.9) 108 (61.0) 50 (66.7) 107 (60.8) 40 (57.1) 114 (67.9) 51 (63.8)

Weight, kg 72.5 (15.1) 72.8 (16.8) 73.9 (17.2) 75.8 (16.0) 74.3 (16.7) 70.8 (14.9) 73.6 (17.3) 73.3 (13.3)

Duration since AD diagnosis, years 26.9 (14.1) 22.4 (16.0) 27.0 (13.5) 21.0 (14.1) 25.4 (13.1) 22.5 (16.5) 26.1 (14.4) 18.7 (14.6)

IGA, n (%)34

189 (52.9)168 (47.1)

78 (57.4)58 (42.6)

96 (54.2)81 (45.8)

39 (52.0)35 (46.7)

98 (55.7)78 (44.3)

34 (48.6)36 (51.4)

90 (53.6)78 (46.4)

44 (55.0)36 (45.0)

EASI 32.5 (12.8) 31.7 (13.2) 31.2 (12.3) 30.7 (12.6) 32.0 (13.3) 34.6 (16.0) 32.7 (12.5) 31.9 (13.1)

Itch NRS ≥4, n (%) 320 (89.6) 115 (84.6) 149 (84.2) 56 (74.7) 145 (82.4) 61 (87.1) 148 (88.1) 66 (82.5)

■ Baseline demographics and disease activity were similar in patients with or without comorbidityData are mean (standard deviation) unless stated otherwise

Frequency of Medical History Comorbidity

n (%)PBO

(N=493)

BARI1-mg

(N=252)

BARI2-mg

(N=246)

BARI4-mg

(N=248)

Prespecified medical history of comorbidity 357 (72.4) 177 (70.2) 176 (71.5) 168 (67.7)

Comorbiditya

Asthma 137 (38.4) 67 (37.9) 84 (47.7) 74 (44.0)

Allergic conjunctivitis 103 (28.9) 53 (29.9) 49 (27.8) 40 (23.8)

Allergic rhinitis 207 (58.0) 111 (62.7) 103 (58.5) 86 (51.2)

Contact dermatitis 37 (10.4) 27 (15.3) 22 (12.5) 17 (10.1)

Food allergy 149 (41.7) 72 (40.7) 73 (41.5) 63 (37.5)

Seasonal allergy 164 (45.9) 78 (44.1) 80 (45.5) 81 (48.2)

Urticaria 22 (6.2) 10 (5.6) 14 (8.0) 10 (6.0)

■ The most common comorbidities were asthma, food allergy, allergic rhinitis, and seasonal allergya ≥5% occurrence, patients with multiple occurrences of the same event are counted under the highest severity

■ The magnitude of response with baricitinib was consistently greater than with placebo■ There were no significant treatment-effect differences between patients with or without comorbidity

** p≤0.01, *** p≤0.001 vs. PBO

Proportion of Patients Achieving Itch NRS ≥4-Point Improvement Response at Week 16a,b

■ The magnitude of response with baricitinib was consistently greater than with placebo■ There were no significant treatment-effect differences between patients with or without comorbidity

* p≤0.05, ** p≤0.01, *** p≤0.001 vs. PBOa Analysis based on patients with Itch NRS ≥4 at baselineb 0=no itch, 10=worst itch imaginable

Proportion of Patients Achieving IGA (0, 1, 2) Response at Week 16a

■ The magnitude of response with baricitinib was consistently greater than with placebo■ There were no significant treatment-effect differences between patients with or without comorbidity

* p≤0.05, ** p≤0.01, *** p≤0.001 vs. PBOa 0=clear, 4=severe

EASI Improvement at Week 16

■ The change from baseline with baricitinib was consistently greater than with placebo■ There were no significant treatment-effect differences between patients with or without comorbidity

* p≤0.05, ** p≤0.01, *** p≤0.01 vs. PBOa LS mean percentage change from baseline = (LS mean change from baseline / overall total mean at baseline) × 100

Itch Improvement at Week 16

■ The change from baseline with baricitinib was consistently greater than with placebo■ There were no significant treatment-effect differences between patients with or

without comorbidity

* p≤0.05, ** p≤0.01, *** p≤0.01 vs. PBOa ADSS Item 2 = How many times did your itch cause you to wake up last night?b In patients with ADSS Item 2 score >1 at baselinec LS mean percentage change from baseline = (LS mean change from baseline / overall total mean at baseline) × 100

Improvement in Sleep Disturbance Due to Itch at Week 16a

** p≤0.01, *** p≤0.001 vs. PBOa LS mean percentage change from baseline = (LS mean change from baseline / overall total mean at baseline) × 100

■ The change from baseline with baricitinib was consistently greater than with placebo■ There was a significant difference in treatment effect between patients with or without

comorbidity (p=0.0143)– The difference was based on the magnitude of the difference between baricitinib

treatment and placebo; the direction of that difference was the same

With

Without

0

20

40

60

80

100

Atopic Comorbidity

Res

pons

e (%

)

**

11.519.920.3

26.729.0 28.632.7

41.3******

***

MonotherapyBARI 1-mg (N=252)

BARI 2-mg (N=246) BARI 4-mg (N=248)PBO (N=493)

N=357 N=177 N=176 N=168 N=136 N=75 N=70 N=80With

Without

0

20

40

60

80

100

Atopic Comorbidity

Res

pons

e (%

)

38.1

51.545.8

64.061.9 61.455.4

63.8***

***

With TCS RescuePBO (N=493) BARI 1-mg (N=252)BARI 2-mg (N=246) BARI 4-mg (N=248)

N=357 N=177 N=176 N=168 N=136 N=75 N=70 N=80

With

Without

0

20

40

60

80

100

Atopic Comorbidity

Res

pons

e (%

)

*

4.42.610.1 12.5

16.6

6.6

21.6 21.2******

*

***

Monotherapy

N=320 N=148 N=145 N=148 N=114 N=56 N=61 N=66With

Without

0

20

40

60

80

100

Atopic Comorbidity

Res

pons

e (%

)

15.912.3

17.6 19.720.7 19.6

28.4 30.3** **

With TCS Rescue

N=320 N=148 N=145 N=148 N=114 N=56 N=61 N=66

With Without

0

20

40

60

80

100

Atopic Comorbidity

Res

pons

e (%

)

**

9.817.618.6 21.3

25.020.0

29.8 32.5***** *

MonotherapyPBO (N=493) BARI 1-mg (N=252)BARI 2-mg (N=246) BARI 4-mg (N=248)

N=357 N=177 N=176 N=168 N=136 N=75 N=70 N=80

With

Without

0

20

40

60

80

100

Atopic Comorbidity

Res

pons

e (%

)

31.7

44.136.2

46.748.952.950.6

45.0

*** ***

With TCS RescuePBO (N=493) BARI 1-mg (N=252)BARI 2-mg (N=246) BARI 4-mg (N=248)

N=357 N=177 N=176 N=168 N=136 N=75 N=70 N=80

n (%)

BREEZE-AD1/AD2

PBO (N=493)

BARI 1-mg (N=251)

BARI 2-mg (N=246)

BARI 4-mg (N=248)

Atopic comorbidity

W (N=357)

W/O (N=136)

W (N=177)

W/O (N=74)

W (N=176)

W/O (N=70)

W (N=168)

W/O (N=80)

Any TEAEMildModerateSevere

213 (59.7)123 (34.5)76 (21.3)14 (3.9)

59 (43.4)35 (25.7)22 (16.2)2 (1.5)

107 (60.5)53 (29.9)45 (25.4)9 (5.1)

28 (37.8)20 (27.0)6 (8.1)2 (2.7)

107 (60.8)63 (35.8)38 (21.6)6 (3.4)

35 (50.0)25 (35.7)8 (11.4)2 (2.9)

107 (63.7)70 (41.7)32 (19.0)5 (3.0)

32 (40.0)22 (27.5)10 (12.5)

0

Serious AEs 13 (3.6) 2 (1.5) 9 (5.1) 1 (1.4) 2 (1.1) 1 (1.4) 3 (1.8) 0

Death 0 0 0 0 0 0 0 0

AEs leading to study discontinuation

2 (0.6) 0 3 (1.7) 0 3 (1.7) 0 2 (1.2) 0

With

Without-80

-60

-40

-20

0

Atopic Comorbidity

LS M

ean

Perc

enta

ge C

hang

eFr

om B

asel

inea

**

-28.5

-49.1

-58.3-51.3

-63.3******

EASI Percentage Change From Baseline

-41.0-43.3

-51.3-55.5

***

With

Without-80

-60

-40

-20

0

Atopic Comorbidity

LS M

ean

Perc

enta

ge C

hang

eFr

om B

asel

inea

***

-15.0

-25.0

-35.3 -34.4

***

Itch NRS Percentage Change From Baseline

-23.4-28.7

-32.8-39.4**

Overview of Adverse Events

■ Most treatment-emergent adverse events were mild or moderate

Overview of Treatment-Emergent Infections

n (%)

BREEZE-AD1/AD2

PBO (N=493)

BARI 1-mg (N=251)

BARI 2-mg (N=246)

BARI 4-mg (N=248)

Atopiccomorbidity

W (N=357)

W/O (N=136)

W (N=177)

W/O (N=74)

W (N=176)

W/O (N=70)

W (N=168)

W/O (N=80)

Patients with ≥1 infection 111 (31.1) 39 (28.7) 64 (36.2) 13 (17.6) 65 (36.9) 19 (27.1) 63 (37.5) 21 (26.3)

Opportunistic infection 0 0 0 0 0 0 0 0

Herpes zoster 1 (0.3) 0 0 0 0 2 (2.9) 0 0

Herpes simplex 10 (2.8) 4 (2.9) 11 (6.2) 2 (2.7) 11 (6.3) 0 8 (4.8) 6 (7.5)

Tuberculosis 0 0 0 0 0 0 0 0

Patients with ≥1 skin infection requiring antibiotic treatment

23 (6.4) 7 (5.1) 5 (2.8) 2 (2.7) 12 (6.8) 3 (4.3) 8 (4.8) 2 (2.5)

■ Safety outcomes for patients with atopic comorbidities were similar to outcomes in the overall population2

PBO (N=493)BARI 2-mg (N=246)

BARI 1-mg (N=252)BARI 4-mg (N=248)

PBO (N=493)BARI 2-mg (N=246)

BARI 1-mg (N=252)BARI 4-mg (N=248)

WeekWeekWeekWeekWeekWeekWeekWeek

With

Without

0

20

40

60

80

100

Atopic Comorbidity

LS M

ean

Perc

enta

ge C

hang

e Fr

om B

asel

inec

8.2 9.112.8

28.526.719.3

26.7 30.2

Change From Baseline in Nights Without Awakenings,b Observed

****** ***

****

N=223 N=97 N=90 N=95 N=72 N=37 N=44 N=42

PBO (N=295)BARI 2-mg (N=134)

BARI 1-mg (N=135)BARI 4-mg (N=138)

PBO (N=435)BARI 2-mg (N=206)

BARI 1-mg (N=205)BARI 4-mg (N=214)

PBO (N=435)BARI 2-mg (N=206)

BARI 1-mg (N=205)BARI 4-mg (N=214)